First Conference on Big Data for Pharmacovigilance Jae MinVicki OsborneSaad A. W. Shakir Meeting Report 19 September 2018 Pages: 1281 - 1284
Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action Anna RadeckaLouise LoughlinJune Raine Special Article Open access 21 August 2018 Pages: 1285 - 1302
Risks of Opioids in ST-Elevation Myocardial Infarction: A Review Anne Henrieke TavenierRenicus Suffridus HermanidesAdriaan W. J. van ‘t Hof Review Article 28 August 2018 Pages: 1303 - 1308
Real World Evidence: Time for a Switch? Rachel E. SobelAndrew BateRobert F. Reynolds Commentary 09 October 2018 Pages: 1309 - 1312
Evaluation of Switching Patterns in FDA’s Sentinel System: A New Tool to Assess Generic Drugs Joshua J. GagneJennifer R. PopovicSarah K. Dutcher Original Research Article 17 August 2018 Pages: 1313 - 1323
Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database Leticia Ortiz de LandalucePere CarbonellJoan-Ramon Laporte Original Research Article Open access 28 June 2018 Pages: 1325 - 1331
Changes in Outpatient Use of Antibiotics by Adults in the United States, 2006–2015 Mallika L. MundkurJessica FranklinElisabetta Patorno Original Research Article 09 July 2018 Pages: 1333 - 1342
Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa Dorina OnoyaKamban HirasenMatthew P. Fox Original Research Article Open access 24 July 2018 Pages: 1343 - 1353
Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project Ola CasterJuergen DietrichJohn van Stekelenborg Original Research Article Open access 24 July 2018 Pages: 1355 - 1369
Comment on “Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project” Cedric BousquetBissan AudehAgnès Lillo-Le Louët Letter to the Editor 19 October 2018 Pages: 1371 - 1373
A Critical Evaluation of Safety Signal Analysis Using Algorithmic Standardised MedDRA Queries Carolyn TieuChristopher D. Breder Original Research Article 16 August 2018 Pages: 1375 - 1385
Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis Patrick ImfeldMichael BodmerChristoph R. Meier Original Research Article 27 August 2018 Pages: 1387 - 1396
Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab Karen SmithSu GolderGraciela Gonzalez-Hernandez Original Research Article Open access 30 August 2018 Pages: 1397 - 1410
Comment on “Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis” Katsuhiro Toda Letter to the Editor 05 October 2018 Pages: 1411 - 1411
Authors’ Reply to Katsuhiro Toda’s Comment on “Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case-Control Analysis” Patrick ImfeldMichael BodmerChristoph R. Meier Letter to the Editor 05 October 2018 Pages: 1413 - 1413
Comment on: “Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring” Alain Braillon Letter to the Editor 17 August 2018 Pages: 1415 - 1416
Authors’ Response to Braillon’s Comment on: “Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring” Mirjam SimoonsAdrie SeldenrijkHenricus Ruhé Letter to the Editor 17 August 2018 Pages: 1417 - 1418
Comment on: “Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs” Courtney M. SuggsRobert L. LevinLiang Zhao Letter to the Editor 19 September 2018 Pages: 1419 - 1421
Authors' Reply to Courtney Suggs and Colleagues’ Comment on: “Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs” Richard A. HansenNing ChengC. David Page Letter to the Editor 19 September 2018 Pages: 1423 - 1424
Comment on “Central Demyelinating Diseases After Vaccination Against Hepatitis B Virus: A Disproportionality Analysis Within the VAERS Database” Carine CohenAnnick HoudeauAlena Khromava Letter to the Editor Open access 29 September 2018 Pages: 1425 - 1427
Authors’ Reply to Cohen et al.’s Comment on “Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database” Julie MouchetBernard Bégaud Letter to the Editor 29 September 2018 Pages: 1429 - 1430
Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience John F. MarcinakMelvin S. MunsakaNeila Smith Correction 17 October 2018 Pages: 1431 - 1437
Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance Victoria NewbouldSteven Le MeurXavier Kurz Correction 20 July 2018 Pages: 1439 - 1440
Correction to: Abstracts of the 18th ISoP Annual Meeting “Pharmacovigilance without borders” Geneva, Switzerland, 11–14 November, 2018 Correction 31 October 2018 Pages: 1441 - 1441
